A fermentation-based bioprocess for producing nutraceutical-enriched compositions from biofuel co-products

Background

The field of animal nutrition and feed supplementation has seen significant advancements in recent decades, driven by the need to improve animal health, enhance the nutritional value of animal-derived foods, and address sustainability concerns within the agricultural and biofuel industries. Ethanol production from corn and milo generates large quantities of co-products such as whole stillage and dried distillers grains with solubles (DDGS), which are primarily used as animal feed. However, these co-products are often limited in their nutritional profile and lack certain bioactive compounds that can confer additional health benefits to animals and, by extension, to humans who consume animal products. At the same time, there is growing interest in incorporating nutraceuticals—compounds with health-promoting or medicinal properties—into animal feeds to improve outcomes such as reduced cholesterol in meat and eggs, enhanced growth, and better overall animal well-being.

Current approaches to enriching animal feeds with nutraceuticals face several challenges. Traditional methods often rely on substrates like rice for fermentation with beneficial microorganisms such as Monascus species, but using rice is costly and diverts a staple human food resource. Supplementing feeds with purified nutraceuticals is also labor-intensive and expensive, requiring multiple processing steps including extraction and purification. Furthermore, the underutilization of ethanol co-products represents a missed opportunity for value addition and improved sustainability. Existing feed supplementation practices may not efficiently enhance the nutritional and functional properties of animal feeds, and often fail to leverage the full potential of available agricultural by-products. These limitations highlight the need for more cost-effective, sustainable, and integrated solutions to produce nutraceutical-enriched animal feeds while maximizing the value of biofuel industry co-products.

Technology

This technology centers on a bioprocess that transforms co-products from corn or milo ethanol fermentation—such as whole stillage or dried distillers grains with solubles (DDGS)—into nutraceutical-rich compositions using the fungus Monascus purpureus. During fermentation, Monascus metabolizes these agricultural by-products to synthesize a suite of valuable secondary metabolites, including monacolin K (lovastatin, a cholesterol-lowering agent), gamma-aminobutyric acid (GABA, a neurotransmitter with metabolic and antihypertensive benefits), and a range of bioactive pigments. The process not only enriches the substrate with higher levels of protein, fiber, and beneficial fatty acids but also reduces crude fat and can generate novel fatty acids not originally present. The resulting product can be dried and directly incorporated into animal feed to improve animal health and product quality, or specific nutraceuticals can be extracted for use in human pharmaceuticals.

What differentiates this technology is its ability to valorize abundant, low-cost biofuel industry co-products—traditionally used as basic animal feed—by converting them into high-value, health-promoting feed additives and nutraceuticals through a single, streamlined fermentation process. Unlike conventional methods that rely on rice (a human food staple) as a fermentation substrate and require multiple production steps, this approach leverages non-food biomass, reduces material and processing costs, and supports sustainability by closing the loop on biofuel by-products. The process is highly adaptable, allowing optimization through strain selection, fermentation conditions, and co-culturing with other microbes to maximize yields of desired compounds. This integrated solution not only enhances the nutritional and functional profile of animal feeds but also creates new opportunities for extracting pharmaceutical-grade nutraceuticals, making it a scalable and eco-friendly advancement for both the animal nutrition and human health sectors.

Benefits

• Utilizes abundant biofuel co-products (corn/milo ethanol fermentation residues), promoting sustainability and waste valorization.
• Produces nutraceutical-rich compositions containing monacolin K (lovastatin), GABA, bioactive pigments, and beneficial fatty acids.
• Enhances animal feed nutritional profile by increasing protein, fiber, and health-promoting compounds while reducing crude fat.
• Enables direct incorporation of fermented products into animal feed, reducing processing steps and costs.
• Offers potential extraction of purified nutraceuticals for human pharmaceutical applications.
• Reduces reliance on rice as a fermentation substrate, preserving a human food staple.
• Fermentation process is flexible and can be optimized using various Monascus strains, co-products, and fermentation methods.
• Improves animal product quality, such as lowering cholesterol in meat and eggs, benefiting animal health and consumer nutrition.

Applications

• Nutraceutical-enriched animal feed production
• Extraction of statins for pharmaceuticals
• Production of GABA supplements
• Bioactive pigment manufacturing

Additional info

A fungal bioconversion process employs *Monascus purpureus* to ferment corn/milo ethanol co-products. This synthesizes nutraceutical compositions containing monacolin K, GABA, and bioactive pigments. The resulting material enhances animal feed with increased protein and beneficial fatty acids, or provides extracted compounds for human pharmaceuticals.